Clinical trials: Metastatic Androgen Independent Prostate Cancer
Prostate Cancer
Efavirenz in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Efavirenz may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well efavirenz works in treating patients with metastatic prostate…
- Trial name
- FAVE (NCT00964002)
- Testing
- efavirenz
- Where
- France
- Volunteers
- 61 people
- Sponsor
- Institut Bergonié
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to determine whether the amount of time before disease progression can be prolonged in participants with metastatic castration-resistant prostate cancer (MCRPC) who receive lorigerlimab in addition to…
- Conditions
- Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance
- Trial name
- NCT05848011
- Testing
- lorigerlimab, docetaxel, Prednisone
- Where
- 61 sites in United States, Australia and 8 more
- Volunteers
- 154 people
- Sponsor
- MacroGenics
Prostate Cancer
Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Calcitriol may cause prostate cancer cells to look more like normal cells, and to grow and spread more slowly. Drugs used in chemotherapy, such as mitoxantrone and prednisone, work in different ways to stop the growth…
- Trial name
- NCT00182741
- Testing
- calcitriol, mitoxantrone hydrochloride, prednisone
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- OHSU Knight Cancer Institute
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel
Drugs used in chemotherapy, such as SB-715992, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00096499
- Testing
- ispinesib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00096304
- Testing
- docetaxel, epirubicin hydrochloride
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Medical University of South Carolina
Prostate Cancer
AZD2171 to Treat Prostate Cancer
Background: AZD2171 (Cediranib) is an experimental drug that inhibits formation of new blood vessels. Tumors need new blood vessels to grow. Preventing the growth of new blood vessels with AZD2171 may inhibit tumor growth.
- Trial name
- NCT00436956
- Testing
- Magnetic Resonance Imaging (DCE-MRI), AZD2171, Prednisone
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- National Cancer Institute (NCI)
Hormone-Refractory Prostate Cancer, Prostatic Neoplasms
YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy
The purpose of this study is to determine if patients who take YM598 in addition to mitoxantrone and prednisone (standard therapy) experience improvement in the pain associated with prostate cancer metastases in the bone.
- Trial name
- NCT00048659
- Testing
- YM598
- Where
- 53 sites in United States, Australia and 8 more
- Sponsor
- Astellas Pharma Inc
Androgen-independent Prostate Cancer
Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)
To determine the time to progression produced by the combination of Novantrone (mitoxantrone) and Erbitux (cetuximab) versus Novantrone alone in metastatic AIPC patients previously treated with docetaxel-based chemotherapy.
- Trial name
- NCT00661492
- Testing
- cetuximab, Mitoxantrone
- Where
- 55 sites in United States
- Volunteers
- 115 people
- Sponsor
- US Oncology Research
Prostatic Neoplasms
Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
This is a Phase II study of docetaxel, bevacizumab, prednisone and thalidomide in patients with androgen independent metastatic prostate cancer who are previously untreated with chemotherapy.
- Trial name
- NCT00089609
- Testing
- Docetaxel, Thalidomide, Prednisone
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00045227
- Testing
- recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, recombinant vaccinia-B7.1 vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer
The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) given with prednisone in patients with androgen-independent prostate cancer, who have not had previous chemotherapy, is safe…
- Trial name
- NCT00350051
- Testing
- Sagopilone (ZK 219477) + prednisone
- Where
- 17 sites in United States, Argentina
- Volunteers
- 53 people
- Sponsor
- Bayer
Prostate Cancer
A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1
This study investigates the use of the patients own immune cells to treat prostate cancer. Cells are taken from the patient and grown in the laboratory to become specialized immune cells called dendritic cells.
- Trial name
- MUC1 (NCT00852007)
- Testing
- DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Hamilton Health Sciences Corporation
Prostate Cancer
A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer
The purpose of this study is to determine whether IMC-A12 or IMC-1121B (ramucirumab) with Mitoxantrone and Prednisone is effective in the treatment of metastatic androgen- independent prostate cancer (APIC).
- Trial name
- NCT00683475
- Testing
- IMC-A12, Mitoxantrone, Prednisone
- Where
- 36 sites in United States
- Volunteers
- 138 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer
Vaccine Therapy in Treating Patients With Non-Metastatic Prostate Cancer
RATIONALE: Vaccines made from tumor cells or dendritic cells may help the body build an effective immune response to kill tumor cells. It is not yet known which vaccine is more effective in treating patients with prostate cancer.
- Trial name
- NCT00814892
- Testing
- allogeneic tumor cell vaccine, therapeutic autologous dendritic cells
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Prostate Cancer
Lycopene in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Lycopene, a substance found in tomatoes, may lower prostate-specific antigen (PSA) levels and slow or prevent the development of prostate cancer.
- Trial name
- NCT00068731
- Testing
- lycopene
- Where
- 18 sites in United States
- Volunteers
- 47 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
PROSTVAC-VF is an investigational cancer vaccine. The vaccine is based on the theory that the immune system can be taught to fight cancer by directing the immune system to attack specific targets found on cancer cells.
- Trial name
- NCT00078585
- Testing
- PROSTVAC®-VF/TRICOM™
- Where
- 47 sites in United States
- Volunteers
- 120 people
- Sponsor
- Bavarian Nordic
Prostate Cancer
Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00258284
- Testing
- capecitabine, docetaxel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Cancer
Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver radioactive tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00081172
- Testing
- lutetium Lu 177 monoclonal antibody J591
- Where
- 3 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostatic Neoplasms
Safety Study of TAK-700 in Subjects With Prostate Cancer.
The purpose of this study is to determine the safety and tolerability of TAK-700 in patients with asymptomatic metastatic, androgen independent prostate cancer.
- Trial name
- TAK-700 (NCT00569153)
- Testing
- TAK-700
- Where
- 19 sites in United States
- Volunteers
- 123 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Prostate Cancer
To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen
This is a randomized, multicenter, single blind, Phase 2 trial of immunotherapy in men with metastatic androgen independent prostate cancer to evaluate sipuleucel-T manufactured with different concentrations of PA2024 antigen
- Trial name
- NCT00715078
- Testing
- sipuleucel-T
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Dendreon